LIVE 1:45 pm – 3:10 pm 4/25/2016 Forum Opening, A War or Moonshot: Where Do We Stand? Creating a Disruptive Cancer Pipeline @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

« 12:00 pm – 1:30 pm 4/25/2016, Discovery Café: Enjoy Lunch with Top Cancer Leadership from across Partners HealthCare @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

LIVE 3:10 pm – 4:00 pm 4/25/2016 3:10 pm – 4:00 pm Curative Therapies: The Economics of Game Changing Science @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston »

LIVE 1:45 pm – 3:10 pm 4/25/2016 Forum Opening, A War or Moonshot: Where Do We Stand? Creating a Disruptive Cancer Pipeline @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

April 25, 2016 by 2012pharmaceutical

LIVE 1:45 pm – 3:10 pm 4/25/2016 Forum Opening, A War or Moonshot: Where Do We Stand? Creating a Disruptive Cancer Pipeline @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

1:45 pm – 1:55 pm Forum Opening: David Torchiana, MD and Anne Klibanski, MD

Torch – $1.5 Billion Budget, management of MGH and BWH – the two top Hospitals in the Nation – significant amount diverted to Cancer Research

Welcome Dana Farber collaborators

1:55 pm – 2:20 pm A War or Moonshot: Where Do We Stand?
2:20 pm – 3:10 pm Creating a Disruptive Cancer Pipeline

Novartis Ballroom

@2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

2016 World Medical Innovation Forum: CANCER, April 25-27, 2016,

Partners HealthCare, Boston, at the Westin Hotel, Boston

ANNOUNCEMENT

Leaders in Pharmaceutical Business intelligence (LPBI) Group

will cover in Real Time using Social Media this Event on

CANCER Innovations

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @Westin in Boston

worldmedicalinnovation.org

1:45 pm – 1:55 pm
Novartis Ballroom

Forum Opening

Introduction by: Anne Klibanski, MD

Chief Academic Officer, Partners HealthCare
Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

David Torchiana, MD

CEO, Partners HealthCare

1:55 pm – 2:20 pm
Novartis Ballroom

A War or Moonshot: Where Do We Stand?

Moderator: Nancy Snyderman, MD, Medical Advisor, GE Healthymagination

War or MoonShoot?
Parameters for being scanned for lung cancer
DNA in the clinic – Participation and proactive sequencing???
Immune-therapy is back
effect on immune system by Cancer
message when cancer comes back

Monica Bertagnolli, MD

Chief, Division of Surgical Oncology, Brigham and Women’s Hospital
Professor of Surgery, Harvard Medical School

As Surgeon – it is a War

Age is #1 RISK for Cancer

when intervention can happen when we can wait

achieve cure — by prevention of malignancy

decrease lung cancer – due to smoke sessetion

sharing data needs improvement

cell cancer need be detected that they do not belong there, they trick the imune system

mutations that drugs are not there for that mutation

How tumor can not hurt you? exsition not cure — but NEVER HARM the Patient by the Tumor

collaboration Public-Private partnerships

Foundations are very important

Cancer has drawn clinicians from chronic diseases

neighboring the stroma vs treating the tumor

not enough progress in studing conditions of the early stage – if you do not know it is there – why search for it

Cancer vs moonshot — all US population to go to the moon, Cancer is still different than going to the moon

Daniel Haber, MD, PhD

Director, MGH Cancer Center, Kurt J. Isselbacher /Peter D. Schwartz Professor of Oncology, Harvard Medical School

blood testing for cancer detection

anti-smoking cancer

if smoking 45 years or more – screening

10 years from now, if early detection – surgery will become rarer

Genetic risk factors known: epigenetics, llife style

reimburse srinkage of tumor for Prevention or diagnostics

challenge HOW to reimburse cancer treatment in a different way

People live with Cancer longer, growth in survivorship

Translational research vs DIscovery, now it is Translational primarily – if no more innovation – nothing to translate in few years

creative engine in an interdisciplinary fashion

NOT all is genetics — it is TISSUE !! very important

Pediatric Cancer: Chemo works well, time from lab to clinic is shorter

it is a WAR, no one discipline can do it alone

2:20 pm – 3:10 pm
Novartis Ballroom

Creating a Disruptive Cancer Pipeline

Some companies characterize creating a successful pipeline of disruptive cancer therapies as an engineering challenge, others arranging building blocks and others integrating capabilities from the marketplace – for many it is all of the above. Considerations are heavily tied to research and innovation and include discovering novel targets, novel single agent drugs and emerging novel mechanisms, new pathways and/or mechanisms of action, new molecular entities and technology acquisition strategies, among others. The panel, top industry leaders, investors and academic experts pulls back the curtain to discuss the considerations in pipeline development, the tradeoffs and what it takes to maintain success over time.

Moderator: Robert Tepper, MD, Partner, Third Rock Ventures, Adjunct Professor, Harvard Medical School

Genomics, new approaches, anti-cancer immuno-therapy, defining the population of responders

BioPharma – develop drugs along the type of cancers

What is new around the corner

clinical trials innovation: what is the frontier

Amgen – pipeline ll drugs vs oncology drugs

Small companies vs Big Pharma

James Bradner, MD, President, Novartis Institutes for BioMedical Research

Gleevec for Leukemia,

gene directed therapy – immune oncology is NOT new,

find ways to use decision points: small molecule selection, combination – guidance by genotypic information ONE type of information

Therapeutic not exists for many alterations, what technology will bring a therapeutic response

chess board: engineered T-cells for Pediatric Leukemia – what Science is needd for new agents

enzymes – gene editing for the immune system

How do Scientists communicate at Novatris — culture was found deeply connected like I knew at Broad

Generationally — connectivity, IT exceptional, pulled Presentations from Basel and SHanghai in minutes, the institution provides infrastructure that was not know in previous generation

open competitive advantages vs silos

George Demetri, MD, Director, Center for Sarcoma and Bone Oncology, Senior Vice President for Experimental Therapeutics, Institute Physician, Dana-Farber Cancer Institute

biotech, Big Pharma and Dana Farber

1970s – leukemias, adults – no cure, Pediatrics ALL – solved

Precision medicine we believe in — diagnostics and treatment requires a long rum, few successs in 03 years of big army fighting

FDA – looks to industry and Academia, approving drugs, safety focus, make easy for Patients to participate in Clinical Trials

focus on activities in the communities, academic centers, efficacy, 3D Printing, DNA organic transformed into cells,

Clinical Trials requires education — to start therapy at vs srart of therapy directly

rare diseases – 60% of Dana Farbers Patients are in Clinical Trial

cost to participate in clinical study — should not be a point

research is done to improve treatment

Cancer Science: only in this area it is so expensive to develop, every biotech is contacting Dana Farber, scientists are investing careers in Cancer

Steve Fawell, PhD, VP, Head Oncology iScience, AstraZeneca

Combination drugs

immuno-oncology

technology and biology areas

cytotoxicity – patients failing treatment

small comapnies wish to create VALUE, big pharma wish a good drug to be developed – some tension there

Keith Flaherty, MD, Director, Clinical Research, MGH Cancer Center, Associate Professor of Medicine, Harvard Medical School

biotech needs to demonstrate very fast success, the molecular and clinical jobs

early drug development

challange: Cancer Biology – acquired resistance, each drug effect of autonomous biology of tumor

need for a shared enterprise among Big Pharma

seeking proof of concept very fast – 1% of relevance to drugs in the future

molecular defined subspace for durable response rate

compensatory mechanism for the majority – de-risking vs focus on a specific type

melanoma is my interest: there is a population for them not treatment helps

Diagnostics and drug development needs to go together – Perfection is now expected ONLY from diagnostics not from Therapeutics

inflammation of tumor at baseline

HIV — how many drugs

repertoire of drugs is unsatisfactory – drugs to colide earlier, wide range od drugs from multiple drug makers — Hospitals face decisions of related to which drug to use

FDA — to establish a Center of Excellence on Cancer

democratize and leverage research and access to existing clinical trials in hospitals vs Big Pharma using CROs

access to information on mutations paired with drugs to identify which of the existing trials is the best for a given Patients

Cancer Biology is in the hands of many small companies, class of therapy is established by interactions and the leadership of the first in class

small companies, Boston-Cambridge eco-system: pathways are known by some lear=ding Scentistist from long time

Sean Harper, MD, Executive Vice President, Research and Development, Amgen

motivation for Academia leaders to move to Industry — the field has moved, molecular biology, sequencing, targets can be successful

Discovery areas: Oncology and Immunology-Genomics were combined – it has energized Scientists to work on autoimmune disorders and oncology Checkpoint inhibitors are an example of the two areas benefiting from the combining of the two areas

FDA was very remarkable on T-cells, melanoma, small trials, speculative, surprising good results. Agency collaborated in a remarkable fashion